Drug Profile
APB R3
Alternative Names: APB-R3; Long-acting IL-18BP; Long-acting interleukin-18 binding proteinLatest Information Update: 22 Jan 2024
Price :
$50
*
At a glance
- Originator APRILBIO
- Class Anti-inflammatories; Antirheumatics; Fab fragments; Proteins; Recombinant fusion proteins
- Mechanism of Action Interleukin 18 binding protein replacements; Interleukin-18 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Adult-onset Still's disease
- Preclinical Liver disorders
Most Recent Events
- 19 Dec 2023 Syneos Health and AprilBio completes a phase I trial for Adult-onset Still's disease (In volunteers) in Australia (IV) (NCT05715736)
- 21 Jun 2023 Preclinical trials in Liver disorders in South Korea (Intraperitoneal) before June 2023
- 21 Jun 2023 Interim pharmacodynamics data from a preclinical studies in Liver disorders presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)